Articles related to NEUROLOGICAL DISORDERS

As this review discovered, repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. Still, the report offers several factors that should be considered before designing future clinical trials.

The new codes, which became effective in January 2020, replaced existing EEG Monitoring codes used for limited electrode set (95950), daily video-EEG (95951), ambulatory EEG (95953), and daily EEG without video (95956). Have you reviewed the new codes and figured it all out?

A single, unifying etiology for FMD is not yet known, and this article from Practical Neurology characterizes diagnosing the disorder as “a process involving a careful history and examination for positive signs to rule in the diagnosis, while considering the differential diagnoses of functional presentations.”

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

A fact-filled video program all about ALZ-801 (valiltramiprosate), an oral medication with a novel mode of action that aims to slow or stop Alzheimer’s disease altogether.

Hear, watch, or read the top-line observations from a Harris Poll that included more than 360 patients and 120 caregivers on the impact of symptomatic neurogenic orthostatic hypotension (nOH). Suffice, many described severe limitations to their ability to perform activities that are necessary for day-to-day living.